Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Article Details

Citation

Copy to clipboard

Gonzalez JP, Clissold SP

Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Drugs. 1987 Dec;34(6):648-61.

PubMed ID

2892662 [ View in PubMed

]

Abstract

Levobunolol is a potent non-selective beta-adrenoceptor blocking agent used for the topical treatment of increased intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. In comparative studies of up to 2 years' duration levobunolol 0.5 to 1% reduced intraocular pressures by about 30% and adequately controlled intraocular hypertension in 50 to 85% of those treated. These results were significantly superior to those produced by placebo and comparable to the responses achieved with ocular timolol in double-blind controlled trials. Levobunolol has been well tolerated, producing only minor changes in objective and subjective ophthalmic and systemic parameters. Adverse reactions resulted in approximately 5% of patients withdrawing from treatment with levobunolol which was equivalent to that observed with timolol. Thus, ocular levobunolol is a well-tolerated and effective therapy for the management of raised intraocular pressure, and is a suitable alternative to ocular timolol in patients with chronic open angle glaucoma or ocular hypertension.

DrugBank Data that Cites this Article

Drugs

Levobunolol

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Levobunolol	Beta-1 adrenergic receptor	Protein	Humans	Yes	Antagonist	Details
Levobunolol	Beta-2 adrenergic receptor	Protein	Humans	Yes	Antagonist	Details